Dr. Santhosh Palani has served on Acrivon's Board since March 2024 and chairs its Nominating & Corporate Governance Committee. He has been founder and CEO of the investment advisory firm PSP Research since November 2024 and was an investment partner at PFM Health Sciences from 2020 to 2024, leading public and private biotechnology investments. Earlier he was a principal at New Enterprise Associates. He currently serves on the board of Pyxis Oncology. Dr. Palani holds a Ph.D. in bioengineering from the University of Pennsylvania, an M.S. in chemical engineering from Texas A&M University and a B.S. in chemical engineering from the University of Madras, and is a CFA charterholder. He serves on Acrivon's Compensation Committee.